Rosetta Financial Statements From 2010 to 2025
| ROSGQ Stock | USD 0.0001 0.00 0.00% |
Check Rosetta Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rosetta Genomics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Rosetta financial statements analysis is a perfect complement when working with Rosetta Genomics Valuation or Volatility modules.
Rosetta |
Rosetta Genomics Company Return On Equity Analysis
Rosetta Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rosetta Genomics Return On Equity | -1.38 |
Most of Rosetta Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rosetta Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Rosetta Genomics has a Return On Equity of -1.3796. This is 94.24% lower than that of the Biotechnology sector and 79.35% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Rosetta Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rosetta Genomics's current stock value. Our valuation model uses many indicators to compare Rosetta Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rosetta Genomics competition to find correlations between indicators driving Rosetta Genomics's intrinsic value. More Info.Rosetta Genomics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Rosetta Genomics' earnings, one of the primary drivers of an investment's value.About Rosetta Genomics Financial Statements
Rosetta Genomics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Rosetta Genomics investors may analyze each financial statement separately, they are all interrelated. The changes in Rosetta Genomics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Rosetta Genomics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 86 people.
Pair Trading with Rosetta Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rosetta Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rosetta Genomics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Rosetta Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rosetta Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rosetta Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rosetta Genomics to buy it.
The correlation of Rosetta Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rosetta Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rosetta Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rosetta Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rosetta Pink Sheet Analysis
When running Rosetta Genomics' price analysis, check to measure Rosetta Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rosetta Genomics is operating at the current time. Most of Rosetta Genomics' value examination focuses on studying past and present price action to predict the probability of Rosetta Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rosetta Genomics' price. Additionally, you may evaluate how the addition of Rosetta Genomics to your portfolios can decrease your overall portfolio volatility.